CMS took an important step on April 16, 2023, expanding coverage of CGM to users of any insulin as well as to individuals who do not use insulin but who experience recurrent Level 2 or a single Level 3 hypoglycemic event.76 These changes are consistent with current American Diabetes Association (ADA) clinical guidelines.37 In light of the evidence reviewed here, there is clearly a growing evidentiary basis for permitting others to access this important technology as well. The gene discussed is INS; the disease is diabetes mellitus.